688321 Shenzhen Chipscreen Biosciences
- 20.96
- -0.14-0.66%
Shenzhen Chipscreen Biosciences News
Shenzhen Microchip Biotechnology Co., Ltd. shareholder return plan for the next three years (2024-2026)
Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Notice on Risk Alerts for Issuing A-Shares to Specific Targets with Diluted Spot Returns in 2024 and the Company\'s Adoption of Corrective Measures and Related Entities\' Commitments
Announcement on early termination of promotion cooperation with Haizheng Pharmaceutical
Announcement on not revising the conversion price of “Microchip Bonds” downwards
Voluntary disclosure announcement on acceptance of the CS231295 tablet clinical trial application
An indicative announcement on the “Microchip Convertible Bonds” expected to meet the conversion price correction conditions
Announcement on the results of convertible debt-to-equity swaps and changes in shares
Voluntary disclosure of the announcement that the company was selected as the sixth batch of specialized, special and new “little giant” enterprises at the national level
Voluntary Disclosure Notice Regarding Acceptance of Clinical Trial Applications for the Treatment of Extensive Small Cell Lung Cancer with Theoroni Capsules
Voluntary disclosure of the announcement regarding the approval of the indications for the use of empagliflozin and metformin hydrochloride in the treatment of type 2 diabetes.
Announcement on the results of convertible bonds and changes in shareholding
Announcement regarding the interest payment for Weichip Convertible Bonds in 2024.
CSI Securities Co., Ltd.'s entrusted management report on Shenzhen Chipscreen Biosciences Co., Ltd.'s issuance of convertible corporate bonds to unspecified objects (2023). Bonds.
Announcement about not adjusting the conversion price of "Wichips Convertible Bonds" downward.
In 2022, Shenzhen Chipscreen Biosciences Co., Ltd. issued convertible corporate bonds to unspecified investors. The tracking rating report is for 2024.
Announcement regarding the credit rating results of the Weichip Convertible Bond Tracking.
Announcement for the Expected Fulfillment of Conversion Price Adjustment Conditions regarding 'Microchip Convertible Bonds'.
Voluntary disclosure of announcements regarding the company's drugs to be included in breakthrough therapeutic categories
Announcement on the adjustment of the conversion price of the convertible corporate bond “Microchip Convertible Bonds” and the suspension and resumption of trading
Analysis
Price Target
No Data
No Data